Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma

Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma

Intrahepatic cholangiocarcinoma is a rare malignancy, which is rich in actionable alterations. Genomic aberrations in the mitogen-activated protein kinase (MAPK) pathway are common, and BRAF exon 15 p.V600E mutations are present in 5–7% of biliary tract cancers (BTC). Dual inhibition of BRAF and MEK...

Full description

Bibliographic Details
Main Authors: Timothy P. DiPeri, Mehmet Demirhan, Daniel D. Karp, Siqing Fu, David S. Hong, Vivek Subbiah, Joann Lim, Leomar Y. Ballester, Jean H. Tayar, Maria E. Suarez-Almazor, Milind Javle, Funda Meric-Bernstam
Format: Article
Language:English
Published: Innovative Healthcare Institute 2022-02-01
Series:Journal of Immunotherapy and Precision Oncology
Subjects:
cholangiocarcinoma
precision oncology
targeted therapy
myositis
Online Access:https://theijpt.org/doi/pdf/10.36401/JIPO-21-18

Internet

https://theijpt.org/doi/pdf/10.36401/JIPO-21-18

Similar Items